Therapy Against Ischemic Injury

Author(s): Giacinta Guarini, Alda Huqi, Paola Capozza, Doralisa Morrone, Francesca Donati, Mario Marzilli

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 25 , 2013

Become EABM
Become Reviewer


The advent of reperfusion therapy constituted a historical change for the management of myocardial infarction (MI) patients. However, shortly after, experimental models recognized an intrinsic damage, related to reperfusion itself, which was termed as ischemiareperfusion injury (IRI). Clinical studies attribute IRI a significant burden of morbidity and mortality observed in patients undergoing successful epicardial reperfusion. Several mechanisms have been identified and, as many strategies, have been investigated to address the phenomenon. In this review we will discuss the current evidence for IRI, pharmacological and non-pharmacological preventive strategies adopted both in experimental models and in clinical practice. Finally, we will try to provide a critical appraisal to the lack of consistent benefit observed in translational medicine.

Keywords: Ischemia-reperfusion injury, no reflow, preconditioning, postconditioning, mPTP, RISK and SAFE pathways, mitochondria, ROS, adenosine.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [4597 - 4621]
Pages: 25
DOI: 10.2174/1381612811319250008
Price: $65

Article Metrics

PDF: 16